Literature DB >> 8955159

Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase. Identification Of the first molecular lesion causing Farber disease.

J Koch1, S Gärtner, C M Li, L E Quintern, K Bernardo, O Levran, D Schnabel, R J Desnick, E H Schuchman, K Sandhoff.   

Abstract

Human acid ceramidase ((AC) N-acylsphingosine amidohydrolase, EC 3.5. 1.23) hydrolyzes the sphingolipid ceramide into sphingosine and free fatty acid. Ceramide is an essential component of all sphingolipids and an important cell-signaling molecule. Moreover, an inherited deficiency of AC activity leads to the lysosomal storage disorder known as Farber disease. Human AC was purified from urine, and 117 amino acid residues were determined by microsequencing. Degenerative oligonucleotide probes were then constructed and used to screen for human fibroblast and pituitary cDNA libraries. Several partial cDNA clones were obtained, and two of these were combined to construct a full-length cDNA containing a 17-base pair (bp) 5'-untranslated sequence, a 1185-bp open reading frame encoding 395 amino acids, a 1110-bp 3'-untranslated sequence, and an 18-bp poly(A) tail. Transient expression of the full-length cDNA in COS-1 cells led to a 10-fold increase in AC activity. In addition, biosynthetic studies carried out in the transfected cells demonstrated that 13-kDa (alpha) and 40-kDa (beta) AC subunits were derived from a common 55-kDa precursor encoded by the full-length cDNA. This protein pattern was identical to that seen in normal human skin fibroblasts. A homoallelic point mutation (T222K) was also identified in the AC gene of a patient suffering from Farber disease, further confirming the authenticity of the full-length cDNA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8955159     DOI: 10.1074/jbc.271.51.33110

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  63 in total

Review 1.  Sphingolipid metabolism in the regulation of bioactive molecules.

Authors:  C Luberto; Y A Hannun
Journal:  Lipids       Date:  1999       Impact factor: 1.880

2.  Peptidase family U34 belongs to the superfamily of N-terminal nucleophile hydrolases.

Authors:  Jimin Pei; Nick V Grishin
Journal:  Protein Sci       Date:  2003-05       Impact factor: 6.725

3.  Cloning and characterization of a wheat neutral ceramidase gene Ta-CDase.

Authors:  Xiumei Yu; Xiaojie Wang; Xueling Huang; Heinrich Buchenauer; Qingmei Han; Jun Guo; Jie Zhao; Zhipeng Qu; Lili Huang; Zhensheng Kang
Journal:  Mol Biol Rep       Date:  2010-11-19       Impact factor: 2.316

Review 4.  Sphingolipids in the DNA damage response.

Authors:  Brittany Carroll; Jane Catalina Donaldson; Lina Obeid
Journal:  Adv Biol Regul       Date:  2014-11-18

Review 5.  Ceramidases, roles in sphingolipid metabolism and in health and disease.

Authors:  Nicolas Coant; Wataru Sakamoto; Cungui Mao; Yusuf A Hannun
Journal:  Adv Biol Regul       Date:  2016-10-11

Review 6.  One gene, many neuropsychiatric disorders: lessons from Mendelian diseases.

Authors:  Xiaolin Zhu; Anna C Need; Slavé Petrovski; David B Goldstein
Journal:  Nat Neurosci       Date:  2014-05-27       Impact factor: 24.884

7.  Substrate specificity, membrane topology, and activity regulation of human alkaline ceramidase 2 (ACER2).

Authors:  Wei Sun; Junfei Jin; Ruijuan Xu; Wei Hu; Zdzislaw M Szulc; Jacek Bielawski; Lina M Obeid; Cungui Mao
Journal:  J Biol Chem       Date:  2010-01-20       Impact factor: 5.157

Review 8.  Ceramide and neurodegeneration: susceptibility of neurons and oligodendrocytes to cell damage and death.

Authors:  Arundhati Jana; Edward L Hogan; Kalipada Pahan
Journal:  J Neurol Sci       Date:  2009-01-14       Impact factor: 3.181

9.  Potent inhibition of Acid ceramidase by novel B-13 analogues.

Authors:  Denny Proksch; Jan Jasper Klein; Christoph Arenz
Journal:  J Lipids       Date:  2010-12-09

Review 10.  Molecular targeting of acid ceramidase: implications to cancer therapy.

Authors:  Youssef H Zeidan; Russell W Jenkins; John B Korman; Xiang Liu; Lina M Obeid; James S Norris; Yusuf A Hannun
Journal:  Curr Drug Targets       Date:  2008-08       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.